3.12%
-25.19%
-69.02%
-78.46%
-81.64%
-97.45%
-96.07%
AI Spotlight on AFMD
Company Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe.Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society.The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Market Data
| Last Price | 1.01 |
| Change Percentage | 3.12% |
| Open | 1 |
| Previous Close | 0.98 |
| Market Cap ( Millions) | 15 |
| Volume | 132840 |
| Year High | 8.95 |
| Year Low | 0.92 |
| M A 50 | 1.74 |
| M A 200 | 3.85 |
Financial Ratios
| FCF Yield | -515.26% |
| Dividend Yield | 0.00% |
| ROE | -193.85% |
| Debt / Equity | 74.96% |
| Net Debt / EBIDTA | -8.41% |
| Price To Book | 0.87 |
| Price Earnings Ratio | -0.21 |
| Price To FCF | -0.19 |
| Price To sales | 17.14 |
| EV / EBITDA | -0.31 |
News
- Dec -09 - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
- Dec -08 - Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
- Dec -06 - AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
- Dec -05 - Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
- Nov -14 - Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
- Nov -14 - Affimed Reports Third Quarter 2024 Financial Results & Business Update
- Nov -06 - Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
- Sep -10 - Affimed to Present at the Cantor Global Healthcare Conference 2024
- Sep -05 - Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
- Sep -05 - Affimed Reports Second Quarter 2024 Financial Results & Business Update
- Sep -04 - Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
- Sep -04 - Affimed Appoints New CEO, Shares Fall on Leadership Change
- Sep -03 - Affimed Appoints Shawn M. Leland as Chief Executive Officer
- Aug -29 - Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
- Jun -12 - Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
- Jun -12 - Affimed Reports First Quarter 2024 Financial Results & Business Update
- Jun -05 - Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
- Jun -04 - Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
- Jun -04 - Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
- Jun -01 - Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Antibodies
Expected Growth : 11.2 %
What the company do ?
Antibodies from Affimed N.V. are bispecific antibodies designed to engage and activate immune cells to combat cancer and other diseases.
Why we expect these perspectives ?
Affimed N.V.'s antibodies exhibit strong growth driven by increasing adoption in cancer treatment, rising demand for targeted therapies, and expanding pipeline of novel candidates. Additionally, strategic partnerships and collaborations fuel innovation, while growing investments in research and development further accelerate growth.
Affimed N.V. Products
| Product Range | What is it ? |
|---|---|
| AFM13 | AFM13 is a bispecific, tetravalent antibody that targets CD30 and CD16A, which is designed to treat CD30-positive malignancies, including Hodgkin lymphoma and peripheral T-cell lymphoma. |
| AFM24 | AFM24 is a bispecific, tetravalent antibody that targets EGFR and CD16A, which is designed to treat EGFR-expressing solid tumors. |
| AFM28 | AFM28 is a bispecific, tetravalent antibody that targets BCMA and CD16A, which is designed to treat multiple myeloma. |
| AFM32 | AFM32 is a bispecific, tetravalent antibody that targets PSMA and CD16A, which is designed to treat prostate cancer. |
Affimed N.V.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Affimed N.V. is moderate, as there are alternative treatments available for cancer patients, but the company's unique approach to immunotherapy provides a competitive advantage.
Bargaining Power Of Customers
The bargaining power of customers is low, as patients and healthcare providers have limited negotiating power in the pharmaceutical industry, and Affimed N.V.'s products are highly specialized.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate, as Affimed N.V. relies on a few key suppliers for raw materials and manufacturing services, but the company's strong relationships and contracts mitigate this risk.
Threat Of New Entrants
The threat of new entrants is high, as the biotechnology industry is highly competitive, and new companies are constantly emerging with innovative technologies and products.
Intensity Of Rivalry
The intensity of rivalry is high, as Affimed N.V. operates in a highly competitive industry with many established players, and the company must continually innovate and differentiate its products to maintain market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 25.08% |
| Debt Cost | 9.33% |
| Equity Weight | 74.92% |
| Equity Cost | 14.20% |
| WACC | 12.98% |
| Leverage | 33.48% |
Affimed N.V. : Quality Control
Affimed N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| EVGN | Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through … |
| SLGL | Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead … |
| MLEC | Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and … |
| EXAI | Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
Moolec Science
A-Score
1-Year Total Return ->
🥉
Evogene
A-Score
1-Year Total Return ->
4
Sol-Gel Technologies
A-Score
1-Year Total Return ->
5
Exscientia
A-Score
1-Year Total Return ->
6
